Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration-Reference-Cited by-同舟云学术

Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration

Published:2017-12-13 Issue:5 Volume:110 Page:486-492
ISSN:0027-8874
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Tibau Ariadna¹,Molto Consolación¹,Ocana Alberto²,Templeton Arnoud J³,Del Carpio Luis P¹,Del Paggio Joseph C⁴,Barnadas Agustí¹,Booth Christopher M⁵⁶,Amir Eitan⁴

Affiliation:

1. Oncology Department, Hospital de la Santa Creu i Sant Pau and Universitat Autònoma de Barcelona, Barcelona, Spain

2. Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain

3. Department of Medical Oncology, St Claraspital and Faculty of Medicine, University of Basel, Basel, Switzerland

4. Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Ontario, Canada

5. Division of Cancer Care and Epidemiology, Queen’s University Cancer Research Institute, Kingston, Canada

6. Departments of Oncology and Public Health Sciences, Queen’s University, Kingston, Canada

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/110/5/486/24797265/djx232.pdf

Reference45 articles.

1. New FDA breakthrough-drug category--implications for patients;Darrow;N Engl J Med.,2014

2. Early accelerated approval for highly targeted cancer drugs;Chabner;N Engl J Med.,2011

3. Can expedited FDA drug approval without expedited follow-up be trusted?;Carpenter;JAMA Intern Med.,2014

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding the Challenges Associated with Approval of Anticancer Products to Facilitate the Regulatory Approvals: A Cross-sectional Study;Current Cancer Therapy Reviews;2024-11

2. Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study;BMJ;2024-08-20

3. From Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond;Pharmaceutics;2024-07-01

4. Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies;JAMA Oncology;2024-05-01

5. The impact of level of documentation on the accessibility and affordability of new drugs in Norway;Frontiers in Pharmacology;2024-02-14